Sean Zhang, MD, FCP
Site Head, Chief Medical Officer
Dr. Sean Zhang is a well accredited Physician-Scientist with more than 30 years’ experience in medical practice, academic research, drug discovery and development. He has ~20-years of pharmaceutical industry work experience in global leading pharmaceutical companies such as Merck, Johnson & Johnson, Bristol-Myers Squibb and GlaxoSmithKline with increasing responsibilities. His extensive experience spans the entire drug discovery, clinical development and life cycle management process.
Before coming to the United States, Dr. Zhang was a Staff Physician and Clinical Investigator in the Chinese Military General (301) Hospital in Beijing, China with a focus on the early diagnosis and treatment of gastrointestinal and liver cancers. He completed his clinical fellowship training program in Clinical Pharmacology at the Clinical Center of National Institute of Health after passing the United States Medical License Examination. Dr. Zhang is a Fellow of American College of Clinical Pharmacology (FCP), and a board member of the Sino-American Pharmaceutical Professional Association (SAPA), an organization with more than five thousand Chinese American pharmaceutical professionals. He has authored more than 30 peer-reviewed publications and is a frequent speaker at multiple national/international conferences/symposiums on translational medicine and early drug development.
Greg Berk, MD
Senior Medical Consultant
Dr. Greg Berk is a senior oncology drug development consultant. He previously served as Chief Medical Officer at Verastem. Previous to this he was President, Chief Medical Officer, and Board Member of Sideris Pharmaceuticals. From May 2012 until January 2014, Dr. Berk was Chief Medical Officer of BIND Therapeutics. Prior to this, Dr. Berk was Chief Medical Officer at Intellikine, a privately held biotechnology company focused on the discovery and development of novel PI3 Kinase and mTOR inhibitors. Intellikine was acquired by Takeda/Millennium in January 2012. Dr. Berk was previously Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company’s overall clinical strategy, including efforts to expand the indications for their lead clinical program (Abraxane®), as well as oversee the clinical development of their entire pipeline. Dr. Berk also served on the integration leadership team during the Celgene acquisition of Abraxis in 2010. Dr. Berk obtained his medical degree from Case Western Reserve University, and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology, at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time Dr. Berk served as an investigator on several industry-sponsored and cooperative group oncology clinical trials, including the pivotal trials for Gleevec® and Avastin®.
Ewa Matczak, MD
Associate VP, Clinical Development/Oncology
Dr. Ewa Matczak is a Medical Oncologist/Hematologist with 10-year’s experience in academic research and medical practice followed by 16 years of drug development at NCI and in the pharmaceutical industry. She worked on global early and late development in solid tumors and hematology, as well as Medical Affairs at companies such as Bayer, Novartis, Eisai, and Pfizer with increasing responsibilities.
Dr. Matczak obtained her MD degree from State University of New York (SUNY) Downstate College of Medicine. Her internal medicine Internship and residency and oncology/hematology fellowship was completed at Columbia Presbyterian in New York. She did her HIV Oncology training and research at Harvard Institute of Medicine/Beth Israel Deaconess where she remained on faculty until she joined the Clinical Trial Evaluation Program (CTEP) at the National Cancer Institute. She was a National Institute of Health (NIH) Intramural Research Awardee. Dr. Matczak organized and led multi-disciplinary translational research clinics in Kaposi’s Sarcoma and HPV. She was a NIH investigator, and an AIDS Malignancy Consortium and Eastern Cooperative Oncology Group member.
Weimin Tang, PhD
Executive Director, Global Business Development & Licensing
Dr. Weimin Tang serves as our Executive Director of Global Business Development. Previously, Dr. Tang served as Vice President of global business development and drug discovery at Crown Bioscience, Prior to Crown Bioscience, Dr. Tang served as Principal Scientist of Johnson and Johnson Research from 2002 to 2010. Over the course of his career, Dr. Tang has served Synaptic Pharmaceuticals (now Lundbeck Pharmaceuticals), American Cyanamid (now Pfizer); Bristol Myer Squibb, Hoechst (now Sanofi) with varies function in research and development.
Dr. Tang received a Bachelor’s Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences and PhD from Rutgers University.
Angela Hee, DMD, MPH
Executive Director, Head of Clinical Operations
Dr. Angela Hee joins HTI from Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) where she was Senior Director and Head of Clinical and Technical Operations. Her role at MTDA focused on building a high functioning clinical operations group especially in CRO management and upgrading technical systems, developing functional procedures and processes that support evolving organizational changes, and contributing to due diligence reviews on compounds for potential in-licensing and development or out-licensing. Prior to MTDA, Dr. Hee was at Otsuka as the medical monitor responsible for several Phase 3 psychiatric indication studies that led to a recent NDA approval. Her career in the pharmaceutical industry started at the Institute of Molecular Biology where she was the trial manager on human growth factor studies in dental and diabetic indications. Dr. Hee has held increasing global Phase 1-4 clinical research leadership positions at AstraZeneca, Johnson & Johnson Consumer and Personal Products Worldwide, Inc., and OraPharma, including strategic development interactions with 5 different FDA divisions and approvals of 2 NDAs, over 20 sNDAs, and 2 device 510Ks.
Dr. Hee received her DMD degree from the University of the Philippines College of Dentistry in the Philippines, and her MPH degree from Harvard University Chan School of Public Health in Boston, MA.